Introduction
Chronic obstructive pulmonary disease (COPD) is a multisystem disease characterized primarily by persistent airflow limitation that is associated with an abnormal inflammatory response of the lungs to noxious particles or gases.(3) Worldwide, COPD is a leading cause of morbidity and mortality, and the frequent comorbidities further impact the overall severity and prognosis of patients with COPD.(4) Depression, postural instability, cognitive and functional impairment are known consequences of cerebral small-vessel disease, and are frequently described extrapulmonary manifestations in patients with COPD.(5-8) However, it is unclear whether COPD is associated with incident cerebral small-vessel disease.
Cerebral small-vessel disease is common among elderly, and cerebral microbleeds are a relatively new marker of the condition.(5, 9) These microbleeds, which consist of hemosiderin deposits in macrophages, can be visualized on Magnetic Resonance Imaging (MRI) as small areas of hypointensity.(10) Microbleeds rarely disappear, making them suitable markers for cumulative cerebrovascular damage. (11) The location of a cerebral microbleed appears to be associated with its underlying disease mechanism: microbleeds in deep or infratentorial locations are suggestive of hypertensive or arteriolosclerotic microangiopathy, whereas those occurring in strictly lobar brain sites are indicative of cerebral amyloid angiopathy. (9, 12) Detection of cerebral microbleeds in patients with COPD and studying their location might increase insight into the pathology substantially. Furthermore, it might also pave the path for better prevention of cognitive and functional impairment in these vulnerable patients. The aim of this study was therefore to investigate whether cerebral microbleeds were more prevalent in subjects with (more severe) COPD and whether microbleed location differed compared to subjects without COPD. Moreover, we wanted to confirm our cross-sectional results into longitudinal analyses to further explore causality. We examined our hypotheses in a large, prospective population-based cohort study of elderly using state of the art MRI.
Methods

Study design
The present study is embedded within the Rotterdam Study, a population based cohort study comprising almost 15.000 participants aimed at assessing the occurrence of, and risk factors for chronic diseases in the elderly. and follow-up MRI examinations (2008) (2009) (2010) . (11, 14) In the longitudinal analysis, only subjects without any microbleed at the time of the first MRI scan were included. The medical ethics committee of the Erasmus Medical Centre, Rotterdam, and the review board of The Netherlands Ministry of Health, Welfare and Sports, approved the study. All participants gave written informed consent.
Assessment of COPD
Diagnosis of COPD was spirometry based as described previously and in more detail in the Online Data Supplement. (15) Spirometry and diffusing capacity were performed using a Master Screen® PFT Pro (CareFusion, San Diego, CA) by trained paramedical personnel according to the ATS/ERS guidelines. (16, 17) In longitudinal analyses, subjects who developed COPD between both MRIs, were excluded, and subjects who developed COPD after the second MRI were treated as controls.
Assessment of cerebral microbleeds on MRI
As described previously and in more detail in the Online Data Supplement, all participants of the Rotterdam Scan Study underwent a multisequence MRI protocol on a 1.5-T scanner and cerebral microbleeds were defined as focal areas of very low signal intensity on T2*-weighted imaging that were not accompanied by evident signal abnormality on other structural sequences. (9, 14) . In accordance with previous literature, microbleed location was classified as lobar (cortical gray matter and subcortical or periventricular white matter), deep (deep gray matter: basal ganglia and thalamus, and the white matter of corpus callosum, internal, external, and extreme capsule) or infratentorial (brainstem and cerebellum). (9, 18, 19) According to the presumed underlying disease mechanism, microbleeds were classified as occurring in strictly lobar brain sites, or occurring in deep or infratentorial locations (whether or not additional to lobar microbleeds). (11) 
Statistical analyses
Differences between subjects with and without COPD were studied using Mann-Whitney U test for continuous variables and Chi-Square test for categorical variables. Logistic regression models were performed to assess the effect of COPD on cerebral microbleeds, both overall and per location class (strictly lobar versus deep or infratentorial). All models were adjusted for age and sex, and additionally, for covariables which changed the risk estimate by more than 5%. More detail on the covariables is provided in the Online Data Supplement. Sensitivity analyses were done by re-examining the associations after exclusion of participants with a history of stroke, in order to assess the confounding effect of previously existent cerebrovascular disease. Individuals with at least one microbleed were consistently compared to individuals without any microbleed. Statistical analyses were performed using SPSS, version 20.0 for Windows (IBM, North Castle, NY).
Results
Cross-sectional study of COPD, severity of airflow limitation and cerebral microbleeds 944 participants of the Rotterdam study had both an interpretable spirometry and brain MRI during the last centre visit. (Figure 1 ) After exclusion of 134 subjects with asthma or a lung function suggestive of a restrictive syndrome, 165 subjects with COPD and 645 subjects without COPD were evaluated. Table 1 shows the baseline characteristics of the crosssectional study population (n=810) with a total median age of 78 years (inter-quartile range[IQR]=6). COPD subjects were slightly older, more often male, (current) smokers, had a lower body mass index and worse lung function. Of the 79 (47.9%) COPD subjects who took drugs for obstructive airway diseases (Anatomical Therapeutic Chemical (ATC) classification R03), 50 (63.3%) used inhaled anticholinergics (R03BB), 48 (60.8%) inhaled β2-sympathomimetics (R03AC), 33 (41.8%) inhaled corticosteroids (R03BA), 55 (69.6%) inhaled fixed combinations (R03AK), and 13 (16.5%) COPD subjects were on treatment with other agents for obstructive airway diseases including xanthines (R03BC, R03C and R03D).
Because 57 (72.2%) COPD subjects were on multiple treatments, summed percentages exceed hundred percent. The 165 COPD subjects were categorized according to the modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification of airflow limitation (20) 
Location of cerebral microbleed
Because the location of a cerebral microbleed tends to be associated with its underlying pathogenetic mechanism, we further investigated the association of COPD with microbleeds occurring in strictly lobar brain sites (amyloid angiopathy), and with microbleeds in deep or infratentorial locations (arteriolosclerotic microangiopathy). (Figure 2 ) Out of 276 subjects who had a cerebral microbleed detected on MRI (Figure 1 ), 177 (64%) had microbleed(s) with a strictly lobar location. In addition, 99 (36%) subjects had microbleed(s) which were located deeply. COPD was not significantly associated with microbleeds occurring in strictly lobar brain sites. (Figure 2 ) In contrast, COPD was significantly associated with deep or infratentorial microbleeds, independent of age, sex, smoking status, and pack-years. (Table 2) The odds ratio was highest and comparable for COPD subjects with severe airflow limitation, COPD subjects with frequent exacerbations, and COPD subjects belonging to GOLD group D. (Table 2 ) Since the airflow limitation in COPD is caused by a combination of small airways disease (bronchiolitis) and loss of elastic recoil due to parenchymal destruction (emphysema), we evaluated continuous lung function parameters. Table 2 shows that per 10% predicted increase in FEV 1 , the prevalence of deep or infratentorial microbleeds decreased by 17%.
Furthermore, per percentage increase in FEV 1 /FVC and diffusing capacity, the prevalence of deep or infratentorial microbleeds decreased by 5% and 2% respectively. Regarding the effect of COPD independent of smoking effects, the prevalence of deep or infratentorial cerebral microbleeds was significantly higher in (ever) smoking COPD subjects (32.7%; 95% CI: 24.4 to 42.2%) compared to (ever) smoking subjects without COPD (10.0%; 95% CI: 7.1 to 13.9%), even after controlling for age, sex, and pack-years (p<0.001). Figure E1 demonstrates the prevalence (%) of subjects without a cerebral microbleed, with strictly lobar cerebral microbleed(s) and with deep or infratentorial cerebral microbleed(s) subdivided by non-smoking control, (ever) smoking control or COPD. A sensitivity analysis excluding the participants with a history of stroke to assess the confounding effect of previously existent cerebrovascular disease, did not change the point estimate of the risk of COPD on cerebral microbleeds nor on deep or infratentorial microbleeds. In 39 well-defined elderly asthmatics and the 645 controls, no significant associations were noted between asthma and (all) cerebral microbleeds, deep or infratentorial microbleeds, or strictly lobar microbleeds (data not shown). In an age and sex-adjusted model of 45 subjects with a spirometry suggestive of restrictive respiratory disease compared to the 645 controls, a restrictive spirometric pattern was significantly associated with (all) cerebral microbleeds (OR 2.6, 95% CI 1.4-4.9 , p=0.002), deep or infratentorial microbleeds (OR 3.8, 95% CI 1.7-8.4, p=0.001) and strictly lobar microbleeds (OR 2.1, 95% CI: 1.0-4.3, p=0.041). The associations with cerebral microbleeds (OR 2.9, 95% CI 1.5-5.6, p=0.002) and deep or infratentorial microbleeds (OR 6.1, 95% CI 2.5-15.1, p<0.001) remained significant after adjustment for age, sex, BMI, smoking status, hematocrit, HDL cholesterol, triglycerides, glucose and serum creatinin (and borderline significant for strictly lobar microbleeds (OR 2.1, 95% CI 1.0-4.6, p=0.064)).
Longitudinal analyses of COPD and incident cerebral microbleeds
In order to investigate causality, longitudinal analyses were performed in 553 participants of the Rotterdam Study who had two MRI brain scans and no cerebral microbleed at the time of the first MRI scan. (Figure E2 ) The median time interval between the two MRI scans was 3.42 years (IQR: 79.5 days) and was not significantly different between subjects with or without COPD (p=0.663). Table E1 in the Online Data Supplement shows the baseline characteristics of the longitudinal study population. COPD subjects were more often male, diabetic, and current smokers. During follow-up, 54 subjects without cerebral microbleeds at the time of the first MRI scan developed a cerebral microbleed, 18 of them at a deep or infratentorial location. (Figure E2) Of the 46 COPD subjects without cerebral microbleeds at the time of the first MRI scan, 5 (10.9%) subjects developed a deep or infratentorial microbleed, compared to 13 (2.6%) of the 507 subjects without COPD. Adjusted for age, sex, and packyears, COPD was associated with a significantly increased risk of developing a deep or infratentorial microbleed (OR 7.1, 95%CI: 2.1-24.5; p=0.002). No significant association was noted for COPD and incident strictly lobar cerebral microbleeds.
Discussion
This large population based study in elderly demonstrates that COPD is associated with a higher prevalence of cerebral microbleeds, a marker of cerebral small-vessel disease determined by MRI.(9) These findings tend to be driven by a greater occurrence of microbleeds in deep or infratentorial locations in subjects with COPD. Furthermore, followup analyses within subjects without a cerebral microbleed at baseline, demonstrated that COPD is an independent risk factor to develop deep or infratentorial cerebral microbleeds.
Our results are in line with two previous cross-sectional studies which showed that patients with COPD had a significantly increased volume of cerebral white matter lesions, which is another marker of cerebral small vessel disease, and known to be associated with microbleeds in a deep or infratentorial region. (2, 21) The location of cerebral microbleeds might give more insight into the underlying mechanism of the association between COPD and cerebral microbleeds. In our population, the association of cerebral microbleeds with COPD was especially strong for microbleeds in deep or infratentorial locations, which are thought to occur by arteriolosclerosis on the basis of hypertensive vasculopathy and lipohyalinosis. (9) Recently, we have demonstrated that COPD subjects had a significant increased prevalence of atherosclerotic macroangiopathy as evidenced by the increased prevalence of carotid artery wall thickening in subjects with COPD.(15) Therefore, carotid artery wall thickening was taken into account as potential confounder in the present study. The current results suggest that COPD might affect large and small blood vessels simultaneously. The systemic inflammation present in a subset of COPD patients, as well as the hypoxia due to progressive airflow limitation and emphysema, might contribute to vessel wall changes resulting in stiffening of arteries and arterioles. (15, 22, 23) Although severity of airflow limitation may not entirely reflect disease activity, our results suggest that cerebral small vessel disease is more present in COPD patients with more severe airflow limitation. (24) In addition, the prevalence of deep or infratentorial microbleeds was more pronounced in COPD subjects with respiratory symptoms or frequent exacerbations.
Interestingly, the effect size of GOLD group B did not seem to be lower than group C.
Previously, a higher mortality risk for group B than C was established. (25, 26) The high percentage of subjects in group A and the very small number in group C are in line with other general population studies. (25) (26) (27) In order to investigate the potential impact of emphysema on the prevalence of cerebral microbleeds, we examined the influence of the diffusing capacity, a measure of the rate of CO uptake by the lungs.(17) The diffusing capacity was significantly associated with the prevalence of deep or infratentorial microbleeds.
The impact of smoking is of particular importance since most COPD patients are current or former smokers, and smoking was previously identified as a risk factor for the presence of cerebral microbleeds.(21) Therefore, we compared the prevalence of microbleeds between COPD subjects who had ever smoked and smoking subjects without airflow limitation. We found that smoking COPD subjects had a significantly higher prevalence of deep or infratentorial microbleeds than smoking subjects without COPD, suggesting that the association between COPD and deep or infratentorial microbleeds could not be explained by smoking solely. These results are in line with previous findings that oxidative stress persists in patients with COPD despite smoking cessation, and has a crucial role in the perpetuation of the inflammation.(3) Previously, the association between impaired lung function and cerebral small vessel disease (white matter lesions) on the one hand and macrovascular disease (carotid intima-media thickness, arterial stiffness) on the other hand, was found to be independent of smoking. (2, 15, 28, 29) Although smoking tends to increase the prevalence of cerebral microbleeds within COPD subjects of our study, our results suggest that an interplay with, or a certain susceptibility for COPD seems necessary before the harmful effect of smoking on deep or infratentorial microbleeds becomes apparent. Potentially, there might be a phenotype more sensitive to smoking, simultaneously developing cardiovascular, pulmonary and cerebral abnormalities. Further research is warranted to explore whether a general phenotype of 'systemic COPD' exists and might benefit from more tailored treatment options. (30) Although the reported longitudinal association is more compatible with a causative role for COPD in the development of cerebral small vessel disease, we cannot exclude that pulmonary manifestations present themselves earlier than cerebrovascular abnormalities.
Aging is another important determinant since cerebral microbleeds gradually increase with age. (21) COPD subjects within the cross-sectional study population were slightly older and therefore all analyses were adjusted for age. However, it is unlikely that the small difference in age could explain the much higher prevalence of cerebral microbleeds compared to the controls, or compared to the age-specific prevalence of cerebral microbleeds described by Poels et al. (21) Strengths of this study are the high quality information derived from state of the art diagnostic imaging techniques which allowed highly sensitive detection of cerebral microbleeds, and the prospective data collection. The population based setting and large sample size of our cohort allowed us to examine COPD patients with a range of disease severity. Furthermore, we made a distinction between different locations of microbleeds in the brain, enabling us to separately assess the prevalence of microbleeds in deep or infratentorial regions versus strictly lobar regions, which embodies a different etiology. (9) A first potential limitation of this observational study is the cross-sectional design of our main analysis. However, the gradual increase in prevalence of deep or infratentorial microbleeds according to severity of airflow limitation, suggests a potential causal mechanism between COPD and cerebral microbleeds. Therefore, we further examined the association longitudinally involving 553 participants of the Rotterdam Study with two MRI scans of the brain and without cerebral microbleeds at the time of the first scan. These results showed that COPD is significantly associated with an increased risk of developing deep or infratentorial microbleeds in the subsequent three years, which further substantiates the plausibility of a causal association between COPD and microbleeds in deep and infratentorial locations. A second consideration is that although COPD is primarily a lung disease, the disease is very heterogeneous and associated with multiple comorbid conditions. The specific role of COPD as a risk factor for cerebral small-vessel disease in patients with multiple comorbidities could therefore be difficult to ascertain. However, the associations between COPD and cerebral microbleeds in our population were independent of known other physiological and cardiovascular risk factors. Finally, we did not perform computed tomography (CT) of the lungs in our population to corroborate emphysema. Although diffusing capacity correlates one of the primary causes of a low DLCO, it is not the gold standard to measure emphysema. (31) In conclusion, the results of this study are compatible with an increased risk of COPD on the development of cerebral microbleeds in deep or infratentorial locations. Given the importance of cognitive and functional consequences, our results might lead to a better recognition of vulnerable patient groups, and enhance research into necessary preventive strategies. 1 Smoking status and packyears were self-reported. 2 Hypertension was defined as antihypertensive medication use and/or an average systolic blood pressure of ≥ 160 mmHg and/or an average diastolic blood pressure of ≥ 100 mmHg. 3 Diabetes mellitus was defined as blood glucose-lowering medication use and/or a non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting serum glucose levels ≥7 mmol/L. Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; DL CO,c = diffusing capacity of the lungs measured using carbon monoxide and corrected for the hemoglobin concentration; FEV 1 = forced expiratory volume in one second; FEV 1 /FVC= proportion of the forced vital capacity exhaled in the first second; HDL= High-Density Lipoprotein (4) A (low risk, less symptoms), B (low risk, more symptoms), C (high risk, less symptoms) and D (high risk, more symptoms). Dyspnea score was based on 5 dyspnea-questions and scored from 0 (never dyspneic) to 5 (even dyspneic at rest) Exacerbations were defined as the total number of moderate and severe exacerbations in the year prior to the MRI examination. Chronic bronchitis was defined as the self-reported presence of cough and sputum for at least 3 months in each of two consecutive years (http://www.goldcopd.org). Detection of cerebral microbleeds in patients with COPD and studying their location might increase insight into the pathology substantially. Furthermore, it might also pave the path for better prevention of cognitive and functional impairment in these vulnerable patients. The aim of this study was therefore to investigate whether cerebral microbleeds were more prevalent in subjects with (more severe) COPD and whether microbleed location differed compared to subjects without COPD. Moreover, we wanted to confirm our cross-sectional results into longitudinal analyses to further explore causality. We examined our hypotheses in a large, prospective population-based cohort study of elderly using state of the art MRI.
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Additional information on the methods
Assessment and staging of COPD
Spirometry and diffusing capacity were performed using a Master Screen® PFT Pro and forced expiratory vital capacity (FVC) < 80% predicted], and asthma patients were excluded. No reversibility tests were conducted. Two COPD subjects within the longitudinal analysis had no interpretable spirometry at the research centre within the study period, however, diagnosis was made by a pulmonologist.
Assessment of cerebral microbleeds on MRI
As previously described, all participants of the Rotterdam Scan Study underwent a multisequence MRI protocol on a 1.5-T scanner (GE Healthcare).(6) A custom-made accelerated three-dimensional T2*-weighted gradient-recalled echo sequence with high spatial resolution and long echo time was used for cerebral microbleed detection. (7) MRI scans were viewed by research physicians blinded to the COPD status of the subject, and presence, number and location of microbleeds was rated. Individuals who had dementia or MRI contraindications were not eligible. Furthermore, participants who had claustrophobia or motion artifacts or susceptibility artifacts on their MRI scans, were excluded from the study population.
Microbleeds were defined as focal areas of very low signal intensity on T2*-weighted imaging that were not accompanied by evident signal abnormality on other structural sequences. 
